Cargando…
Research on the Effects of the Chronic Treatment With Different Doses of Urocortin 2 in Heart Failure Rats
Corticotropin-releasing factor (CRF) receptor type 2 (CRF(2)) exists in both cardiomyocytes and neurocytes. The purpose of this research was to explore if chronic treatment with urocortin 2 (UCN2), a CRF(2) receptor agonist, at different doses can improve prognosis and regulate the expression of CRF...
Autores principales: | Yang, Li-Zhen, Chen, Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595674/ https://www.ncbi.nlm.nih.gov/pubmed/31263386 http://dx.doi.org/10.1177/1559325819860018 |
Ejemplares similares
-
Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure
por: Stirrat, Colin G., et al.
Publicado: (2016) -
Linking stress with urocortin in rats
por: Balraj, Manikandan, et al.
Publicado: (2023) -
Effects of Urocortin 2 Versus Urocortin 3 Gene Transfer on Left Ventricular Function and Glucose Disposal
por: Giamouridis, Dimosthenis, et al.
Publicado: (2018) -
The evaluation of the clinical utility of urocortin 1 and adrenomedullin versus proBNP in systolic heart failure
por: Yıldırım, Erkan, et al.
Publicado: (2017) -
Urocortins in the mammalian endocrine system
por: Squillacioti, Caterina, et al.
Publicado: (2019)